Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
09/2001
09/05/2001EP1130122A2 Methods for the diagnosis of polymorphisms in the human EP1-R gene
09/05/2001EP1130098A2 Mammalian osteoregulins
09/05/2001EP1130017A2 Azole derivatives and their use as superoxide radical inhibitors
09/05/2001EP1129718A2 Therapeutic uses of bactericidal/permeability increasing protein products
09/05/2001EP1129715A1 Use of magnesium, calcium and silicon for the healing of different diseases and to the general well-being
09/05/2001EP1129714A1 Use of tiludronic acid and its derivatives in poultry for the preparation of a medicine for preventing and treating osteoporosis
09/05/2001EP1129350A1 Methods for identifying modulators of bs69 activity
09/05/2001EP1129199A2 Cell signaling polypeptides and nucleic acids
09/05/2001EP1129193A1 Chemokine beta-7
09/05/2001EP1129189A2 Human cell surface receptor proteins
09/05/2001EP1129188A1 Pge synthase and methods and means for modulating its activity
09/05/2001EP1129108A1 Caspases and apoptosis
09/05/2001EP1129089A1 Spiro-indolines as y5 receptor antagonists
09/05/2001EP1129086A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
09/05/2001EP1129084A2 Ppar gamma ligands
09/05/2001EP1129077A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors
09/05/2001EP1129074A2 Antrhranilic acid amides and the use thereof as medicaments
09/05/2001EP1129068A1 Bicyclic signal transduction inhibitors, composition containing them and uses thereof
09/05/2001EP1128838A1 A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
09/05/2001EP1128815A1 Process for preparing oral calcium compositions
09/05/2001EP1128813A1 An inhalation system
09/05/2001EP0873304B1 Metalloproteinase inhibitors
09/05/2001CN1311796A Peptide antiangiogenic drugs
09/05/2001CN1311789A Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
09/05/2001CN1311775A Pyrrole substituted 2-indolinone protein kinase inhibitors
09/05/2001CN1311682A Pharmaceutical compositions and uses for androst-5-ene-3beta, 17 beta-diol
09/05/2001CN1311678A Substituted tricyclic pyrazole derivatives with protein kinase activity
09/05/2001CN1311676A Compound that inhibit the binding of integrins to their receptors
09/05/2001CN1311629A Inhibitors of transcription factor NF-KB
09/05/2001CN1311027A Medicine for curing rheumatoid arthritis, bony arthritis and rigid spinal imflammation
09/05/2001CN1311025A Medicine for curing lupus erythematosus etc. immune diseases induced diseases
09/04/2001US6285537 Stress-follower circuit configuration
09/04/2001US6284872 Tendon-inducing compositions
09/04/2001US6284801 Antirheumatic agents
09/04/2001US6284777 Carbohydrazide protease inhibitors
09/04/2001US6284773 Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
09/04/2001US6284768 Src family SH2 domain inhibitors
09/04/2001US6284730 Administering parathyroid hormone
09/04/2001US6284540 Neuronal trophic support and cell differentiation by introducing nucleotide sequence
09/04/2001US6284515 Signal recognition particle polypeptides and polynucleotides
09/04/2001US6284464 Inhibition of binding of Hox and homeodomain-containing proteins and uses thereof
09/04/2001US6284268 Cyclosporin, synergistic
08/2001
08/30/2001WO2001063244A1 Solution and crystal structures of mmp-13 active site and uses thereof
08/30/2001WO2001062942A2 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
08/30/2001WO2001062932A1 Antagonistic selective binding agents of osteoprotegerin binding protein
08/30/2001WO2001062905A2 Integrin antagonists
08/30/2001WO2001062795A1 COMPOUNDS RELATED TO OR DERIVED FROM GFRα4 AND THEIR USE
08/30/2001WO2001062793A2 Estrogen receptor beta variants and methods of detection thereof
08/30/2001WO2001062789A1 Human polynucleotides, polypeptides, and antibodies
08/30/2001WO2001062775A2 Novel antiarrhythmic peptides
08/30/2001WO2001062758A1 Pteridine compounds for the treatment of psoriasis
08/30/2001WO2001062757A1 Novel compounds
08/30/2001WO2001062756A1 Pyridinylimidazoles
08/30/2001WO2001062751A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
08/30/2001WO2001062750A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
08/30/2001WO2001062742A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
08/30/2001WO2001062733A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
08/30/2001WO2001062729A1 Novel compounds
08/30/2001WO2001062728A1 Novel compounds
08/30/2001WO2001062721A1 Novel use of phenylheteroalkylamine derivatives
08/30/2001WO2001062714A1 Novel phenylheteroalkylamine derivatives
08/30/2001WO2001062713A1 Novel phenylheteroalkylamine derivatives
08/30/2001WO2001062704A1 Novel use of phenylheteroalkylamine derivatives
08/30/2001WO2001062341A2 Combination product for the treatment of obesity
08/30/2001WO2001062285A1 Use of il-18 inhibitors
08/30/2001WO2001062283A2 Mucosal adjuvant formulation
08/30/2001WO2001062252A1 Tyrosine kinase inhibitors
08/30/2001WO2001062251A1 Tyrosine kinase inhibitors
08/30/2001WO2001062250A1 Thiazolium compounds and treatments of disorders associated with protein aging
08/30/2001WO2001010430A3 Use of estrogen compounds for prevention and treatment of ischemic damage
08/30/2001WO2000044682A9 Biodegradable glass compositions and methods for radiation therapy
08/30/2001WO2000040733A9 Human cyclic nucleotide pdes
08/30/2001WO2000040597A9 Method and composition for angiogenesis inhibition
08/30/2001US20010018447 Il-8 receptor antagonists
08/30/2001CA2683009A1 Use of il-18 inhibitors
08/30/2001CA2401063A1 Solution and crystal structures of mmp-13 active site and uses thereof
08/30/2001CA2401036A1 Pyridinylimidazoles
08/30/2001CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
08/30/2001CA2400948A1 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
08/30/2001CA2400923A1 Tyrosine kinase inhibitors
08/30/2001CA2400875A1 Tyrosine kinase inhibitors
08/30/2001CA2400831A1 Estrogen receptor beta variants and methods of detection thereof
08/30/2001CA2400797A1 Therapeutic agents
08/30/2001CA2400694A1 Thiazolium compounds and treatments of disorders associated with protein aging
08/30/2001CA2400435A1 Novel compounds
08/30/2001CA2400434A1 Novel compounds
08/30/2001CA2400293A1 Novel compounds
08/30/2001CA2400040A1 Integrin antagonists
08/30/2001CA2399298A1 Use of il-18 inhibitors
08/30/2001CA2398275A1 Human polynucleotides, polypeptides, and antibodies
08/30/2001CA2397705A1 Compounds related to or derived from gfr.alpha.4 and their use
08/30/2001CA2397234A1 Novel use of phenylheteroalkylamine derivatives
08/30/2001CA2396971A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
08/30/2001CA2396960A1 Novel use of phenylheteroalkylamine derivatives
08/29/2001EP1127883A2 Oxamides as IMPDH inhibitors
08/29/2001EP1127882A1 Tetrazole compounds as thyroid receptor ligands
08/29/2001EP1127878A1 3,4 - substituted pyrazoles for the treatment of inflammation
08/29/2001EP1127869A1 Novel compounds and medicinal use thereof
08/29/2001EP1127578A1 Remedies for bone metabolic errors
08/29/2001EP1127577A2 Ligand for the c-kit receptor and methods of use thereof
1 ... 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 ... 820